Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Isoginkgetin inhibits lung cancer cell progression through miR-27a-5p/APEX1 axis

Langjie Wu, Li Xu

Nanjing University of Chinese Medicine, Nanjing 210023, Jiangsu Province, China;

For correspondence:- Li Xu Email: xulinjucm@126.com

Accepted: 16 August 2022 Published: 30 September 2022

Citation: Wu L, Xu L. Isoginkgetin inhibits lung cancer cell progression through miR-27a-5p/APEX1 axis. Trop J Pharm Res 2022; 21(9):1859-1865 doi: 10.4314/tjpr.v21i9.7

© 2022 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To determine the influence of isoginkgetin on the progression of pulmonary carcinogenesis.

Methods: A549 cells exposed to isoginkgetin were transfected with miR-27a-5p mimetic and suppressor, as well as short hairpin RNA against apurinic/apyrimidinic endo-deoxyribonuclease 1 (sh-APEX1) for 24 h. Then, the proliferative, migration and invasive potential of A549 cells were determined using CCK-8, wound healing and Transwell assays, respectively. The association between miR-27a-5p and APEX1 was determined by dual-luciferase reporter assay.

Results: Isoginkgetin significantly suppressed A549 cell proliferative, migration and invasive activities (p < 0.05). Moreover, isoginkgetin significantly increased miR-27a-5p expression. Furthermore, miR-27a-5p suppressor annulled the influence of isoginkgetin on lung cancer progression. More importantly, the inhibitor directly targeted APEX1, and negatively modulated APEX1 expression (p < 0.05). However, APEX1 knockdown annulled the enhancing effect of miR-27a-5p inhibitor on A549 cell viability, migration and invasion (p < 0.05).

Conclusion: Isoginkgetin exerts an anti-lung cancer effect via miR-27a-5p/APEX1 axis. Thus, it is a potential therapy for the management of lung cancer; however, clinical studies are required to validate these findings of this study.

Keywords: Isoginkgetin, MiR-27a-5p, APEX1, Pulmonary tumor, Lung cancer